Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a leading treatment in the fields of diabetes and obesity, with recent preclinical and clinical studies indicating significant benefits in the management and treatment of MASLD
And critically, this benefit persisted 17 weeks after drug discontinuation
And the company "disclaims any liability for the medical or pharmaceutical services provided through its platform." Spotting red flags While the Ousia situation is unfortunate for the patients involved, it's an example of the regulatory system working the way it's supposed to, says Brunner
24.Rosenstock J, Frias J, Jastreboff AM, et al
These medications work by mimicking a natural hormone that helps regulate hunger and blood sugar
The value of ongoing treatment extends beyond cosmetic weight maintenance